Status:
COMPLETED
Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier
Lead Sponsor:
University of Turku
Collaborating Sponsors:
Chr Hansen
Fennobon oy, Karkkila, Finland (provides the tablets for the pacifier)
Conditions:
Dental Caries
Infectious Diseases
Eligibility:
All Genders
1-4 years
Phase:
PHASE4
Brief Summary
Aims: 1. To develop a food supplement containing a health-promoting probiotic bacteria (B. lactis BB12) and xylitol to be administered with a novel soft, possibly occlusion-friendly pacifier. 2. Test...
Detailed Description
Xylitol is known to reduce counts of mutans streptococci (ms) as well as mother-child transmission of ms. Possibly xylitol delivered to infants could positively influence colonization/metabolism of ms...
Eligibility Criteria
Inclusion
- The infant is healthy
- The family agrees to use the novel slow-release pacifier
- The infant starts to use the pacifier before the age of 3 months
Exclusion
- The child is not healthy
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT00638677
Start Date
June 1 2004
End Date
August 1 2012
Last Update
January 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Health Care Centre
Muurame and Korpilahti, Finland, 40950